Selective oestrogen receptor modulators (SERMs), such as clomiphene citrate, are thought to primarily function as oestrogen antagonists to the pituitary gland to drive gonadotropin release, which in turn stimulates spermatogenic and steroidogenic testicular function (2). The tolerability of clomiphene therapy has been reported in a systematic review that found the self-reported incidence of side effects, most commonly, mood changes, and breast tenderness, is from 4 to 11%, and there has been no evidence of clinically significant changes in lipid profiles, bone density, haemoglobin, or prostate-specific antigen (5). However, no randomised controlled trials have compared clomiphene to testosterone replacement (5).
After T levels are in the therapeutic range with CC, laboratory testing is performed every 6 months. Patients with a less-than-satisfactory increase in serum T, whose LH level does not rise or rises minimally, may benefit from a CC dose increase. During follow-up, the T panel includes total T, free T, sex hormone–binding globulin, LH, estradiol, prostate-specific antigen, and complete blood count. After CC is initiated, T laboratory assessments should be scheduled every 4 weeks until therapeutic T levels are reached. In our clinical practice, our initial T panel includes total T, free T, LH, sex hormone–binding globulin (SHBG), estradiol, dual x-ray absorptiometry scan, prostate-specific antigen (PSA), and complete blood count (CBC). CC is a mixture of enclomiphene (62%), which is a trans isomer with pure antiestrogen effect, and zuclomiphene (38%), which is a cis isomer that has a mixed action with a predominant estrogen receptor agonistic property.
The American Urological Association and European Association of Urology guidelines recommend CC as an off-label treatment option, mainly in men with low T who have interest in fertility and in men with T deficiency who have infertility (for pathway, see Figure 1).9 Patients who have expressed concerns about testicular atrophy observed with exogenous T during T therapy counseling are also excellent candidates for CC. Currently, CC is used off-label for T deficiency and male infertility.7 CC is well tolerated, with only a minority of patients in clinical trials experiencing adverse events, such as vasomotor flushing (10%), abdominopelvic discomfort (6%), nausea and vomiting (2%), breast discomfort (2%), headache (1%), and visual symptoms (eg, blurred vision, photophobia, and diplopia). CC also raises follicle-stimulating hormone levels to potentially improve spermatogenesis.
Meaning that, in most cases, in order for low levels of testosterone to be increased, it is dependent on a medication taken consistently and throughout one’s life. Men with low testosterone have a 33% higher risk of death from any cause than men with normal testosterone levels regardless of age, physical activity, or lifestyle. Studies suggest that men over 50 years of age with low testosterone levels may be at a higher risk of death within 20 years than men with normal levels of testosterone. TRT alone often reduces or eliminates sperm production, but Clomid may help preserve fertility by keeping LH and FSH active, though results vary by individual. In summary, TRT gives strong and fast testosterone replacement but can harm fertility. In these cases, Clomid can support the brain and testicles while TRT provides stable testosterone levels. These hormones then tell the testicles to make more natural testosterone and sperm.
Hypogonadal symptoms are subjective, which can complicate patient diagnosis and identify success with treatment. However, we anticipate this data will serve as a reference to determine sample size in future work comparing TST and CC for hypogonadal symptoms. While both men on CC and TST had improvements in hypogonadal symptoms, men on TST experienced greater symptom resolution as measured by qADAM Table 1. Variability in levels was obviated by the random nature of the draw and the number of patients surveyed. These men underwent hormone estimation and were treated for benign urological conditions such as erectile dysfunction and lower urinary tract symptoms. All men had two separate values of early morning total serum testosterone During the same study period, 52 eugonadal men who were not receiving TST or CC were included as a control group for comparison. After approval from the Institutional Review Board, we assessed hypogonadal symptoms using the ADAM and qADAM questionnaire.
Instead, it works by encouraging the body to restart and increase its own hormone production. Unlike testosterone replacement therapy (TRT), Clomid does not give the body outside testosterone. Regular blood tests are required to check testosterone levels, blood counts, and other hormones. When testosterone levels drop too low, men can feel tired, lose muscle, gain fat, or have problems with sex drive and fertility. Testosterone Replacement Therapy, often called TRT, is a medical treatment for men who have low testosterone levels.
In carefully selected patients, especially those with low or low-normal LH levels, it has an excellent chance of increasing serum T levels. For patients using an aromatase inhibitor for extended periods, some concern exists for bone density loss due to a reduction of the estradiol levels. In men with elevated estradiol levels (≥60 pg/mL), decreasing the CC dose usually results in normalization of estradiol levels; however, some patients may require the addition of an aromatase inhibitor.

Gender: Female

Social links